PMDA drug package insert
ゲムシタビン点滴静注液200mg/5mL「サンド」
PMDA Prescription drug · サンド株式会社 · package insert Sep 30, 2025
Key facts
| Brand names | ゲムシタビン点滴静注液200mg/5mL「サンド」, ゲムシタビン点滴静注液1g/25mL「サンド」 |
|---|---|
| Nonproprietary names | ゲムシタビン塩酸塩 |
| Companies | 製造販売／サンド株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 代謝拮抗性抗悪性腫瘍剤 |
| Therapeutic category codes | 874224 |
| YJ codes | 4224403A1026, 4224403A2022 |
| Approval numbers | 22400AMX01186000, 22400AMX01187000 |
| Package insert edition | 第5版 |
| Package insert date | Sep 30, 2025 |
| PMDA document key | 270428_4224403A1026_1 |
| PMDA company code | 270428 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: